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1. Introduction 
Polymyositis (PM) and dermatomyositis (DM) are systemic autoimmune diseases of 
unknown aetiology in which the skeletal muscles are the main targets (Bohan & Peter, 1975). 
Despite the improvement obtained in recent years with new therapeutic options, their 
prognosis remains poor, with higher rates of morbidity and mortality (Dalakas, 1991, 2001). 
Due to the rarity of the disease, few well-designed studies have been published and, to the 
best of our knowledge, only five randomised controlled trials have been carried out (Choy, 
2002). A low incidence of the disease, a characteristic relapsing/remitting or chronic and 
persistently active course, a lack of agreed standardised criteria for diagnosis and for 
assessment of disease activity makes it difficult to carry out and to compare studies. 
Conventional first line therapy is based on glucocorticoids and their use in many patients 
requires long-term use to control disease. Many patients suffer from the side effects of 
glucocorticoids while others can be refractory to first-line therapy. Thus, there is often the 
need to add immunosuppressive or immunomodulatory agents both to improve the 
disease’s response and to reduce the risk of long-term complications linked to 
glucocorticoids (Choy, 2009).  
Among the treatment options, the use of intravenous immunoglobulin is still matter of 
debate. 
In this chapter we describe the use of intravenous immunoglobulin in inflammatory 
myopathies, revising the literature and reporting our experience. Most of the patients with 
polymyositis or dermatomyositis receive an immunosuppressant such as azathioprine, 
methotrexate, cyclosporine A or mycophenolate mofetil. We decided to verify if the use of 
intravenous immunoglobulin as add-on treatment with cyclosporine A or mycophenolate 
mofetil could improve the outcome or reduce the rate of side effects that are usually linked 
to the immunosuppressant. The subcutaneous administration of immunoglobulin could be 
considered as an alternative to intravenous immunoglobulin. In primary immunodeficiency, 
subcutaneous immunoglobulin has been demonstrated to be linked to a lower incidence of 
adverse reactions, with reliable efficacy and improvement in the quality of life of treated 
subjects. We have been the first to publish a series of seven patients with immune-mediated 
myopathies treated with subcutaneous immunoglobulin. Here we present data relating to a 
larger series. Finally, our intention is to review the data related to the mechanisms of action 
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of immunoglobulin in immune-mediated diseases, in particular underlining the different 
proposed mechanism of intravenous and subcutaneous immunoglobulin. 
2. Intravenous immunoglobulin in inflammatory myopathies 
2.1 Background 
Intravenous immunoglobulin is a therapeutic preparation of pooled polyspecific IgG 
obtained from the plasma of a large number of healthy individuals. The preparations were 
commercialized in the early 1980s to replace intramuscular preparations of polyspecific IgG, 
which were the only available substitutive therapy at that time for patients with primary or 
secondary immunodeficiencies. For patients with primary immunodeficiencies, intravenous 
immunoglobulin (or subcutaneous immunoglobulin) remains the treatment option of 
choice. 
Despite the large number of autoimmune diseases treated with intravenous 
immunoglobulin, guidance on the clinical usage is limited to only three conditions: 
idiopathic thrombocytopenic purpura, Guillian-Barrè syndrome and Kawasaki disease (rev. 
in Elovaaraa et al., 2008). In other neurological conditions, such as chronic inflammatory 
demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and in acute 
exacerbations and short-term treatment of severe myasthenia gravis, their use is codified 
(Elovaaraa et al., 2008). 
Because of the costs, finite supply and time required for the patient receiving intravenous 
therapy, there is a need to rationalize and prioritize the disorders for which, based on 
currently available evidence, intravenous immunoglobulin is adopted. In France, the Comité 
d’Evaluation et de Diffusion des Innovations Technologiques (CEDIT) -Intravenous 
Immunoglobulin Expert Group, aims to identify scientifically validated uses and issue 
recommendations regarding the usage of intravenous immunoglobulin (Mouthon, 2006). 
Guidelines for the use of immunoglobulin have also been developed in the United Kingdom 
(UK Department of Health, 2009), Canada (Mydlarski, 2006; Feasby et al., 2007), Australia 
(Australian Health Minister, 2009) and elsewhere.  
For most of the diseases, intravenous immunoglobulin is not always used as a first-line 
therapy. It may be administered as a steroid-sparing agent and in certain conditions may 
represent an alternative to other available therapeutic approaches, such as 
immunosuppressants, plasma exchange or monoclonal antibodies. Intravenous 
immunoglobulin is also often employed to treat diseases that are refractory to other 
treatments or where conventional therapies result in unacceptable side effects. Combination 
therapy of intravenous immunoglobulin with immunosuppressants has been applied 
successfully in several conditions, including autoimmune vasculitis, and chronic 
inflammatory myopathies (Hartung et al., 2009; Harvey, 2005).  
In 1987, Roifman et al. described the first patient with refractory polymyositis successfully 
treated using intravenous immunoglobulin, whereas in 1991 Lang et al. were the first to 
highlight the beneficial use of intravenous immunoglobulin in the treatment of 
dermatomyositis. Several additional papers have since been published. However, a review 
of the available literature about the use of intravenous immunoglobulin in inflammatory 
myopathies shows the lack of randomised controlled trials due to the difficulty of 
conducting high quality randomised controlled trials in rare diseases. Despite the different 
significance and rationale regarding the use of intravenous immunoglobulin treatment in 
polymyositis and dermatomyositis, the majority of studies reported the use in mixed 
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populations of patients with both diseases. Moreover, in most studies, intravenous 
immunoglobulin has been used in association with other drugs, such as 
immunosuppressants. It is thus difficult to evaluate optimal strategies and efficacy: safety 
ratio in inflammatory myopathies. Here we present a brief revision of the most relevant 
studies on the use of intravenous immunoglobulin in inflammatory myopathies. The 
application in combined treatment with immunosuppressant is analysed in Paragraphs 3 
and 4. 
2.2 Mechanisms of action of intravenous immunoglobulin 
Intravenous immunoglobulin was first introduced in the middle of the twentieth century for 
the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an 
improvement of immune-mediated thrombocytopenia in patients receiving intravenous 
immunoglobulin for immunodeficiencies (Imbach et al., 1981). This opened a new era for the 
treatment of autoimmune conditions with intravenous immunoglobulin. Since then, 
intravenous immunoglobulin has become an important treatment option in an ever-
increasing number of autoimmune diseases (Arson et al., 2009; Kivity et al., 2010; Mimouni 
et al., 2011) and, more recently, for the treatment of tumor metastases   (Damianovich et al., 
2009). Immune dysregulation and loss of self-tolerance are the keystones of autoimmunity 
(Agmon-Levin et al., 2011). There is a large body of evidence that intravenous 
immunoglobulin has the ability to modulate immune reaction at several cellular levels (T 
and B cells, macrophages), interfere with antibody production and degradation, modulate 
the complement cascade, and effect the cytokine network. Despite success in clinical 
application, the precise mechanism of action is not yet clear, but several non-mutually 
exclusive mechanisms have been proposed to explain the beneficial effects of intravenous 
immunoglobulin.  
To understand how intravenous immunoglobulin reverses inflammation in autoimmune 
disease, it is helpful to consider how immunoglobulin G (IgG) auto-antibodies cause 
inflammation. IgG molecules are the most abundant antibody class in the sera of humans; 
they are a family of molecules consisting of four subclasses which vary in their serum 
prevalence and capacity to trigger effector functions, such as binding to cellular Fc-receptors 
for IgG or activating the complement pathway. They seem to have the unique feature of 
initiating pro- and anti-inflammatory reactions: they are the primary mediators of protective 
humoral immunity against pathogens, but they can also be pathogenic. Acting as cytotoxic 
molecules or as immune complexes, IgG auto-antibodies are the principal mediators of 
autoimmune diseases. This pro-inflammatory activity mainly depends on the presence of 
cellular Fc-receptors for IgG.  
Aschermann et al. (2010) proposed a possible explanation based on the interaction 
interference of cellular Fc-receptors on IgG (FCR), and the complement components of the 
Fc-fragment which could prevent the auto-antibodies-mediated FCR activation by blocking 
FC and FCR interaction. Anthony et al. (2008) describe a model wherein sialylated IgG Fc 
protein interacts with a currently unidentified sialic acid-specific receptor on specific 
regulatory macrophages in the marginal zone of spleen. This consequently enhances the 
expression of the Fc receptor IIB on effector macrophages, highlighting that Fc receptor 
has a critical role in mediating the therapeutic effects of intravenous immunoglobulin. The 
mechanisms by which high doses of pooled, monomeric IgG provide anti-inflammatory 
activity have been the subject of much speculation, stemming from the fact that IgG can 
form many different binding interactions through both their antigen binding and Fc 
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domains. In some cases, antigen binding alone might be sufficient to mediate the anti-
inflammatory effects attributed to intravenous immunoglobulin, for example, by blocking 
interactions between a pro-inflammatory ligand and its receptor or by neutralizing its ability 
to elicit an inflammatory response.  
Moreover, due to their presence in natural auto-antibodies against the receptors sialic acid 
binding immunoglobulin (Ig)-like lectin (Siglec)-8 and Siglec-9 that mediate cell death, anti-
proliferative effects and inhibition of cellular activities, intravenous immunoglobulin may 
exert anti-inflammatory properties by increasing the concentration of natural anti-Siglec 
autoantibodies in blood and tissues (Von Gunten et al., 2008). Due to the content of anti-
Siglec-8, the usefulness of intravenous immunoglobulin can be hypothesised in 
hypereosinophilic syndrome or in Churg-Strauss syndrome, because of the documented 
death’s induction by natural antibodies against Siglec-8 and Siglec-9 present in intravenous 
immunoglobulin in both eosinophils and neutrophils in a concentration-dependent manner. 
In a controlled trial regarding Churg-Strauss syndrome it was documented that all patients 
in the intravenous immunoglobulin group were in remission with a significantly favourable 
outcome, compared to controls, which remained after three years. (Danieli et al., 2004).  
It is possible that not all IgG in intravenous immunoglobulin is effective and in all 
probability the involved mechanisms vary from one disease to another. The different 
molecular and cellular pathways involved could explain the wide spectrum of diseases in 
which intravenous immunoglobulin could exert its immunomodulatory and anti-
inflammatory properties. Particular intravenous immunoglobulin activities are also believed 
to be related to the sialylation of IgG through which they become functional in restricted 
subset of diseases such as inflammatory-ones (Seite et al., 2008).  
Due to the method of preparation, the content of immunoglobulin product is variable, 
including natural antibodies and natural auto-antibodies that play a major role in its activity 
(Seite et al., 2008; Vani et al., 2008; Schwartz-Albiez et al., 2009). Other relevant supposed 
mechanisms of action take account of modulation of idiotype-anti-idiotype dimers network 
by binding idiotypic determinants of auto-antibodies; activation, differentiation and effector 
functions of T and of antigen-presenting cells; modulation of B cells via the antigen receptor; 
and interferences with activation of complement and the cytokine network (Seite et al., 
2008). 
In regard to inflammatory muscle diseases, which have different clinical, histological, and 
immunopathological features, the mechanism of action may be different according to the 
properties of individual diseases. The cause of polymyositis and dermatomyositis is 
unknown, but an immune-mediated pathogenesis is strongly implicated.  
As illustrated by Dalakas (2006) intravenous immunoglobulin is thought to work by 
inhibiting complement consumption and intercepting membrane attack complexes, 
suppressing cytokines, adhesion molecules and fibrogenetic factors, and altering 
biologically relevant immunoregulatory or tissues remodelling genes. Resolution of the 
aberrant immunopathological parameters, including interception of complement activation 
products and down-regulation of T cells, intercellular adhesion molecule-1 (ICAM-I), 
vascular cell adhesion molecule (VCAM), transforming growth factor (TGF)-b and major 
histocompatibility complex (MHC)-I molecules, was also noted. 
Dermatomyositis is histologically characterised by complement-mediated microangiopathy 
beginning with complement activation in the periphery that eventually leads to the 
formation of membrane attack complexes, which are deposited on the capillaries causing 
destruction of endomysial capillaries. A number of cytokines and chemokines are thought to 
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be in involved in the process. These molecules may also be responsible for the up-regulation 
of the major histocompatibility complex (MHC) class I antigen and signal trasducer and 
activator of transcription (STAT) 1 expression on the perifascicular’s muscle fibre. The actual 
effectiveness of intravenous immunoglobulin was demonstrated by Dalakas (2006) in a 
double-blind placebo-controlled study. His results demonstrated the improvement in 
muscle cytoarchitecture, down-regulation of cytokine and adhesion molecules, effect on 
complement activation and MAC formation and the improvement of the muscle 
microvasculature. Down-regulation of intercellular adhesion molecule-1 (ICAM-I) more 
than likely has an effect on the exit of activated T cells from the capillaries toward the 
muscle fibres, reducing inflammatory cells infiltrate. Another possible effect is the down-
regulation of TGF-β and TGF-β mRNA, which induces chronic inflammation and fibrosis if 
in excess, as seen in the tissue of patients with dermatomyositis, where it is in generally up-
regulated. Consequently, intravenous immunoglobulin facilitated neovascularisation and 
normalisation of the capillaries and muscle fibres.  
In polymyositis the muscle injury appears to be T-cells mediated and directed against 
unknown antigens expressed on the sarcolemma of the muscle fibres. A severe perturbation 
of peripheral blood T cell TCR repertories was displayed, characterized by the presence of 
antigen specific T-cell with killer/effector phenotype (Mizuno et al., 2004). Thus, CD8+ 
cytotoxic T cells clonally expand and lead to muscle fibres necrosis via perforin pathway, 
according to the observed rearrangement of T-cell-receptor genes among autoinvasive T 
cells and expression of co-stimulatory molecules, adhesion molecules and cytokines 
(Dalakas, 2010).  
With intravenous immunoglobulin it is thus possible to restore immunoregulation and 
normal immune homeostasis (Gurcan et al., 2010; Seite et al., 2008).  
2.3 Intravenous immunoglobulin in dermatomyositis 
With regard to dermatomyositis, a Cochrane review article looking at randomised 
controlled studies (Choy, 2009) identified only the pioneering trial of Dalakas (1993) in 15 
patients with treatment-resistant disease which compared monthly infusions of 2 g/kg of 
immunoglobulin for three months in association with pre-existing low-dose glucocorticoids 
to placebo. The study demonstrated a statistically significant improvement in muscle 
strength measured by mean scores on the neuromuscular symptom scale (P = .035) and the 
modified Medical Research Council scale (from 76.6 to 84.6; P = .018; with a  mean difference 
of 9.50 (95% confidence interval (CI) 4.33 to 14.67) in the treated group. Even though the trial 
measured muscle strength after only three months, the improvements, even in cutaneous 
manifestations, lasted for several weeks. This trial remains the fundamental work 
demonstrating that intravenous immunoglobulin is a beneficial strategy in dermatomyositis. 
The successful use of intravenous immunoglobulin has also been highlighted in other 
studies that show the improvement of 75% to 92% of adults using this treatment modality 
for refractory disease (Gelfand, 1989; Mastaglia, 1998; Marie, 2001). A recent work by 
Gottfried et al. (2000) indicated that remission was documented in particular in patients 
with predominant cutaneous symptoms, absence of autoantibodies, without accompanying 
neoplasia. 
Based on expert consensus, Feasby et al. (2007) conclude that intravenous immunoglobulin 
is recommended, in combination with prednisone, for patients with dermatomyositis who 
have not satisfactorily responded to glucocorticoids. Intravenous immunoglobulin is 
recommended, in association with immunosuppressants, as a steroid-sparing option or as 
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the first-line treatment in life-threatening disease (Feasby et al., 2007). With regards to 
treatment dose and duration, the reported dose is usually 2g/kg, given for two/five days in 
adult patients. In a single treatment course the maximum dose should be 2g/kg. In patients 
responding to this treatment, every attempt should be made to determine the minimum 
effective dose and the use of intravenous immunoglobulin should be continued only if there 
are objective measures of sustained effectiveness.  
2.4 Intravenous immunoglobulin in polymyositis 
The application of intravenous immunoglobulin in polymyositis has not yet been assessed 
with a randomised trial. Their efficacy was highlighted by Cherin et al. in 1991 with a study 
of 20 patients with chronic and refractory polymyositis or dermatomyositis showing clinical 
improvement of fifteen patients (75%) and biochemical improvement in all of them (Cherin, 
1991). The subsequent follow-up, with an increased series including 35 patients with 
refractory dermatomyositis or polymyositis, presented pooled data confirming the 
improvement of patients treated with this regime (Cherin & Herson, 1994). The authors 
documented a significant improvement in mean muscle power (P =0.01) with a reduction in 
mean steroid dose (P =0.05) and a decrease in creatine kinase levels (P =0.01). The same 
group presented data on the only published non-randomised controlled trial specifically 
addressed to polymyositis (Cherin et al., 2002). This study reported clinical improvement in 
71% of patients with significant improvement in muscle power, muscle disability scores, and 
creatinine kinase levels (P <0.01). All of the 22 patients who received intravenous 
immunoglobulin were able to significantly reduce the dose of glucocorticoids (P <0.05). In 
conclusion, in polymyositis, intravenous immunoglobulin can be considered as an 
alternative therapeutic option in patients who do not respond to conventional first-line 
treatment (glucocorticoids). Dose and duration of the treatment are as recommended for 
dermatomyositis (Feasby et al., 2007; Elovaara et al., 2008).  
Despite intravenous immunoglobulin demonstrating adequate efficacy and rapid onset of 
beneficial effects, there are no indications for its use as first-line therapy. The use of 
intravenous immunoglobulin, in an attempt to replace glucocorticoids as first-choice 
treatment to avoid steroid-related myopathy in six adult patients with dermatomyositis and 
in five with polymyositis, did not lead to a significant increase in muscle strength, although 
creatine kinase levels significantly decreased (Cherin et al., 1994). Only three patients 
showed significant clinical improvement. The low success rate obtained by intravenous 
immunoglobulin as first-choice in inflammatory myopathies, compared to their usual 
efficacy in association with glucocorticoids in chronic refractory diseases, suggests a 
synergistic action on both cellular and humoral systems (Cherin et al., 1994). More recent 
studies, in accordance with previous literature, confirm indication of the value of 
intravenous immunoglobulin as a second-line agent in patients with dermatomyositis and 
polymyositis (Cherin, 2008; Dalakas, 2010).  
2.5 Other indications of intravenous immunoglobulin  
Besides the cutaneous and muscle involvement, intravenous immunoglobulin has been 
evaluated in other clinical manifestations of inflammatory myopathies. A rapid onset of 
therapeutical effects was substantiated by Marie et al. (2010) in a recent retrospective 
multicentre study reviewing 73 patients with oesophageal involvement in which 
intravenous immunoglobulin (1 g/kg daily for two consecutive days each month for at least 
seven months) produced improvement within two weeks after the first infusion with a 
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clinical resolution or a marked improvement of oesophageal clinical involvement in 65 
patients (89%),  thus suggesting their use as first-line therapy in life-threatening oesophageal 
manifestations. This data confirms previous studies in smaller series (Marie et al., 1999; 
Cherin et al., 2001). Contrasting results have been documented in interstitial lung disease 
associated with polymyositis and dermatomyositis, in which only a small number cases 
show benefits from intravenous immunoglobulin (Suzuki et al., 2009). 
Intravenous immunoglobulin may also be an alternative option when other drugs are not 
recommended, especially during pregnancy and in breast-feeding mothers. Pregnancy in 
association with an inflammatory myopathy is a rare event, therefore any published data is 
primarily based on case reports or very small groups of patients (Silva et al., 2003; Mosca et 
al., 2005; Williams et al., 2007). Even in this context, intravenous immunoglobulin has been 
shown to be very effective in the treatment of inflammatory myopathies, in particular in 
dermatomyositis (Cherin et al., 2002), and is widely used for various autoimmune 
conditions during pregnancy. It is also used in the treatment of other pregnancy 
complications, such as idiopathic thrombocytopenic purpura and recurrent miscarriages, 
and appears to be safe and well tolerated by pregnant patients (Branch et al., 2001).  
2.6 Our experience with intravenous immunoglobulin in polymyositis and 
dermatomyositis 
We report our experience on the use of intravenous immunoglobulin only associated with 
glucocorticoids in polymyositis and dermatomyositis diagnosed according to the Bohan and 
Peter criteria (1975). Despite alternative classifications being previously proposed and the 
fact that this classification presents some limitations it is the most widely used set of criteria 
in the literature. 
 
 Definition 
Diagnosis of polymyositis 
and dermatomyositis 
Bohan and Peter’s criteria (1975):  
Symmetrical weakness, usually progressive, of the limb-girdle 
muscles 
Muscle biopsy evidence of myositis 
Elevation in serum of creatine kinase levels 
Electromyographic triad of myopathy 
Characteristic dermatologic features of dermatomyositis 
Active disease Decreased skeletal muscle strength assessed using the Medical 
Research Council scale (Miller et al., 1992); 
Elevation of creatine kinase for at least 2 months; 
Typical electromyographic features (Kimura, 1989; Wilbourn, 
1993)
Refractory disease Inadequate response to steroid and/or at least 2 
immunosuppressants given for at least two months; 
OR 
Steroid-dependency: flare-up when the steroid dose was 
reduced to less than 0.25 mg/kg/day; 
OR 
Steroid-resistance: non-responsiveness to high-dose steroid 
treatment (at least 1 mg/kg/day for six weeks)
Relapse Disease reactivation after a remission lasting six  months or 
more 
Table 1. Working definitions used in this chapter. 
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The data of the ten patients in which we used intravenous immunoglobulin were 
extrapolated from our series of 74 patients with polymyositis and dermatomyositis, 
prospectively followed up in our Department. 
There were five cases each of polymyositis and dermatomyositis in one male and nine 
females (all Caucasian) with a median age of onset at 49 years (range 28-63 years). In six 
patients the disease was particularly aggressive with severe muscle involvement and 
dysphagia. Associated clinical features were arthritis (four patients), Raynaud’s 
phenomenon (other four), interstitial lung disease (two patients) and cardiovascular 
involvement (one case). Before treatment serum creatine kinase values were 2326.5 U/l 
(range 637-5500). ANA and anti-ENA positivity were detected in two cases each. Disease 
duration prior to treatment was 17 months (range 4-131), and the median follow-up period 
was 82 months (range 30-170 months). Intravenous immunoglobulin was given on 
occurrence of refractory (7 patients) or relapsed disease (3 patients), definitions of which are 
illustrated in Table 1. 
Initial therapy was based on oral steroids (prednisone 1mg/kg/daily) for one month and 
then slowly tapered to 5-10 mg every other week. Intravenous immunoglobulin was infused 
at 1 g/kg (5g/hour) on two consecutive days each month for six months, followed by three 
further cycles given every other month. The response to treatment was evaluated as 
outlined in Table 2. 
 
Complete remission 
an increase in strength of at least one 
Medical Research Council grade and 
normalisation of the serum creatine kinase 
levels. 
Partial remission 
when only one of the above criteria was 
fulfilled 
Relapse 
recurrence of active disease after a 
remission lasting six months or more 
Table 2. Parameters employed to evaluate the response to treatment. 
After one month of therapy we documented a partial improvement of muscle strength 
associated with a decrease in creatine kinase levels. At one year follow-up this result was 
confirmed, with six patients in complete remission and three in partial remission (Figure 1). 
The last patient dropped out from the study for meningism related to the intravenous 
immunoglobulin infusion. At long-term follow-up (mean 82 months), we could observe 
three relapses, two of which in patients with previous relapsing-remitting recurrences 
(respectively after 31 and 61 months from the beginning of the treatment). 
The treatment was well tolerated with a low incidence of mild adverse events (nausea and 
vomiting) which could be successfully managed by reducing the speed of infusion. All 
patients reported a good tolerance profile of the intravenous administration of 
immunoglobulin. In Dalakas’ study (1993) of dermatomyositis no adverse events were 
reported. In the study of Cherin and Herson (1994) no patients stopped infusions because of 
side effects. Accordingly to the literature, the treatment with intravenous immunoglobulin is 
generally a safe procedure, when given in a slow infusion rate in well-hydrated patients, 
and avoiding patients with known risk factors (Katz et al., 2007). Our data, in accordance 
with the literature, confirms our previous findings (Danieli et al., 2009b) that intravenous 
immunoglobulin is an effective and safe option as second-line therapy in patients with 
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refractoriness to steroids or with relapsing-disease. Subjects treated with intravenous 
immunoglobulin achieve a clinical and functional remission in a high percentage of cases 
which is maintained at long follow-up period. 
 
 
Fig. 1. Outcome and treatment response in 10 patients treated with glucocorticoids and 
intravenous immunoglobulin. 
3. Cyclosporine A and intravenous immunoglobulin in inflammatory 
myopathies 
3.1 Introduction 
The use of cyclosporine is widely accepted in organ rejection, other studies emphasizes its 
importance in the therapy of systemic lupus erythematosus (Moroni et al., 2009) and other 
immune-mediated disease such as inflammatory myopathies. The following presents our 
experience with this drug in a large series of patients with polymyositis and 
dermatomyositis, testing the hypothesis if the add-on of intravenous immunoglobulin could 
improve the outcome or reduce the rate of side effects usually linked to the 
immunosuppressant’s use. Finally, we report the revision of the literature related to the use 
of cyclosporine A in polymyositis and dermatomyositis.  
Cyclosporine is a pro-drug in which its immune effects are secondary to a relative selective 
inhibition of T cell activation. In the cytoplasm, cyclosporine A, after binding to its specific 
cytoplasmic receptor cyclophillin, interferes with calcineurin, a complex of phosphatases 
crucial for the progression of the events that ultimately lead to the lymphocyte proliferation. 
During the physiological immune response, the contact between antigen-presenting cells 
and lymphocytes triggers a strong influx of calcium ions into lymphocytes, with calcineurin 
activation and subsequent dephosphorylation of a family of proteins called nuclear factor 
activating T cells (NFAT). The dephosphorylation mediated by calcineurin leads nuclear 
factor activating T cells (NFAT) to enter the nucleus and promote the synthesis of 
interleukin-2 that, in turn, activates the lymphocyte proliferation. By interfering in this 
(3 PM. 4 DM) 
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cascade, cyclosporine may alter the production of the pro-inflammatory cytokines that 
interplay at different levels among the cellular, immunological and biochemical mediators 
of inflammation. Cyclosporine A may hamper the pro-inflammatory cytokines that promote 
the activation, the maintenance of the immune inflammation, and the migration of the 
lymphocytes to target organs. The main role of cyclosporine A resides thus in the 
interference with T autoreactive cells, while it has little impact on humoral immunity.  
3.2 Our experience with cyclosporine A and intravenous immunoglobulin in 
inflammatory myopathies 
Since 1992, we used three different cyclosporine A-based regimens to treat 24 patients with 
definite myositis according to the Bohan and Peter criteria (1975). The 24 patients had either 
dermatomyositis (12 cases) or polymyositis (12 cases); subjects with connective tissue-
associated, cancer-associated or inclusion body and those with juvenile myositis were 
excluded. The disease was newly diagnosed in seven patients, three of them had 
glucocorticoid refractoriness (Group I). The other 17 patients presented with refractory 
disease, as indicated by non-responsiveness to high-dose steroid treatment or to 
methotrexate and/or azathioprine (nine cases, Group II) or the recurrence of a previously 
quiescent disease (eight cases, Group III). All of the patients had active disease, as confirmed 
by the parameters of increased median values of creatine kinase levels (in all cases), Medical 
Research Council grade (in all cases), the electromyographic myogenic changes (in all cases) 
and the histological characteristics (in 75% of the 18 patients who underwent muscle 
biopsy). The baseline characteristics of the three groups of patients were homogenous, as 
shown in the following table. 
 









PM/DM 3/4 4/5 5/3 
Men /women 2/5 3/6 1/7 
Age of onset  
(years) 
34 48 35 
Baseline serum CK 
levels (U/l) 
706 2584 2468 
Baseline MRC scale 74.4 73.4 68.8 
Disease duration * 
(months)  
14 24 35 
Duration of follow-
up (months)  
40 57 59 
* Before the start of indicated treatment. 
Table 3. Baseline characteristics of the three groups of patients treated with different 
cyclosporine A-based regimens. Data are expressed as median. Abbreviation: AZA, 
azathioprine; CsA, cyclosporine A; CK, creatine kinase; DM, dermatomyositis; IVIg, 
intravenous immunoglobulin; MRC, Medical Research Council; MTX, methotrexate; PDN, 
prednisone; PM, polymyositis.  
As customary, the treatment was based on oral prednisone, which was started at 1 
mg/kg/day and then slowly tapered to an average of 0.25 mg/kg every other day. Initially, 
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oral cyclosporine A was given as 3 mg/kg/day for six months, and then reduced to a 
maintenance dose of 2 mg/kg/day. Patients were given microemulsion (Sandimmun 
Neoral ®, Novartis) which has a better bioavailability and more predictable 
pharmacokinetic properties. In the 17 patients with refractory disease (Group II and III), 
intravenous immunoglobulin were infused at 1 g/kg (5g/hour) on two consecutive days 
each month for six months, followed by three further cycles given every other month. In all 
of the patients, the first treatment period lasted one year during which the patients were re-
evaluated every three months. The parameters used to evaluate the response to treatment 
are outlined in Table 2. The mean follow-up of the entire series as a whole is five years. The 
responses in the three groups are shown in Figure 2.  
 
 
Fig. 2. Response to cyclosporine A associated or not with intravenous immunoglobulin in 24 
patients with Polymyositis and dermatomyositis. 
At the end of the one-year treatment period, we did not document any significant difference 
among the three treatment groups. Indeed, five of the patients in group I had a partial 
response, one was in complete remission and one relapsed eight months after the start of 
treatment. All of the patients in group II and III had improved. In the following period, 
positive results were documented almost exclusively in patients treated with cyclosporine A 
associated with intravenous immunoglobulin (Groups II and III). In group I, one patient was 
in clinical and functional remission 19 months after the start of treatment; the other five 
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cases were still in partial remission. In Group II, all of the patients improved with a 
complete remission in six out of nine patients, and one patient was able to maintain a 
complete remission without any further treatment; only one patient relapsed. In group III all 
of the patients were in persistent remission after having discontinued all treatment. Globally 
82% (14/17) maintain a complete remission at the end of the follow-up period. 
The statistical analyses revealed a significant difference at the end of the follow-up period 
between patients in remission with intravenous immunoglobulin and those treated only 
with cyclosporine A and prednisone (P <0.001, chi-square analysis). We could not detect any 
other correlation between the response to treatment in the three groups and other variables 
such as the kind of myositis (polymyositis or dermatomyositis), the duration of the disease 
prior to the treatment with intravenous immunoglobulin and cyclosporine A, or the kind of 
organ involvement. 
No new or major side effects leading to the interruption of treatment were recorded during 
the trial. In 30% of the patients treated with cyclosporine A we documented minor adverse 
effects consisting of hypertrichosis (three cases) minor gastrointestinal disturbance (nausea 
or vomiting in two cases), gingival hyperplasia (one case), transient increase in serum 
creatinine levels (one case).  
3.3 Literature review on the use of cyclosporine A in inflammatory myopathies 
We revised the English language literature related to the use of cyclosporine A in myositis. 
Since 1976, reports have been published of more than 100 patients with polymyositis and 
dermatomyositis treated with cyclosporine A. In early trials, cyclosporine A was given at 
high doses, ranging from 7.5 to 10 mg/kg/day, in patients with disease unresponsive to 
glucocorticoids or immunosuppressants. As reported, the disease improved, but 
unacceptable side effects were documented in the majority of patients. In more recent years, 
improved knowledge of the drug made it possible to lessen the dosage of cyclosporine A, 
with a proportional decrease of side effects. Cyclosporine A, usually between 2 and 5 
mg/kg/day, allowed for a complete remission in 70% of cases, even in those with refractory 
disease (Danieli et al., 2002; Dankò &  Szegedi, 1991; Qushmaq et al., 2000; Vencovsky et al., 
2000). Two retrospective studies of respectively ten (Dankò &  Szegedi, 1991) and twelve 
(Sanchez Román et al., 1995) patients have suggested the efficacy of cyclosporine A as a 
valid second-line therapy in refractory dermatomyositis. The only randomized controlled 
trial that has evaluated the impact of cyclosporine A in the treatment of polymyositis and 
dermatomyositis was carried by Vencovsky et al. (2000). The authors could not document 
any significant difference between cyclosporine A and methotrexate in terms of efficacy and 
toxicity evaluated at 6-month. In the majority of the cited reports, a good clinical response 
was documented within the first weeks of treatment. 
The efficacy of cyclosporine A was principally evaluated in the treatment of interstitial lung 
disease associated with myositis. The two first reports of respectively eight (Maeda et al., 
1997) and five (Nawata et al., 1999) patients confirmed its effectiveness, in particularly when 
used early. Other later reports confirm these data, with a complete or partial remission in 
more than 50% of the patients (Kameda et al., 2005; Kotani et al., 2008). It is important to 
remember that most patients typically died of respiratory failure related to interstitial 
pneumonia. 
The usefulness of cyclosporine A in myositis seems to be improved by the association with 
intravenous immunoglobulin. Saadeh et al. (1995) were the first to describe a patient with 
dermatomyositis who improved after being treated with cyclosporine A and intravenous 
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immunoglobulin. This preliminary report is in line with our experience, in which 82% of 
treated patients reached a complete remission. The patients had a particularly severe 
disease, due to the presence of non-responsiveness to high-dose steroid treatment or a 
previous relapse. Our data at long-term follow-up reinforces these results, with a highly 
statistically significant difference detected at the end of the follow-up period when 
compared to patients treated with prednisone and intravenous immunoglobulin. The 
association of intravenous immunoglobulin and low-dose cyclosporine A produces 
improved control of disease activity and keeps the least amount of glucocorticoids. 
In literature, no serious side effects are generally described, but 8-15% of patients treated 
with cyclosporine A develop arterial hypertension, hypertrichosis, tremor and transient 
renal dysfunction (Qushmaq et al., 2000). Other adverse events linked to the use of 
cyclosporine A are hyperlipaemia and diabetes. All these events are usually dose related. It 
is extremely important to keep the dose of cyclosporine A at 3 mg/kg/day to avoid 
untoward side effects. It is also recommended to avoid cyclosporine A in patients with renal 
impairment (creatinine clearance <60 ml/min) and/or uncontrolled arterial hypertension, 
and to carefully monitor the serum creatinine and potassium levels. Revising the literature, 
we documented that 20% of the patients with inflammatory myopathies treated with 
cyclosporine A experienced a major side effect such as renal toxicity and arterial 
hypertension. These percentages are lower in subjects treated with cyclosporine A and 
intravenous immunoglobulin, with 5% of patients reporting renal dysfunction and none 
arterial hypertension. Despite these statistics, the conceivable value of intravenous 
immunoglobulin is that its use makes it possible to reduce the doses of glucocorticoids and 
cyclosporine A in most patients, thus lowering the rate of side effects linked to use of these 
drugs.  
While treating patients with cyclosporine A it is important to slowly taper the drug to avoid 
the risk of hyperacute relapse of the disease, as it has been reported in patients with 
systemic lupus erythematosus (Radhakrishnan et al., 1995). To improve the tolerance to the 
drug, some authors advocate the single daily administration, that has been demonstrated to 
be as effective than the bis in die administration but with fewer side effects in patients with 
organ transplant  (Tarantino et al., 2004) and in those with idiopathic nephrotic syndrome 
(Rasche et al., 2007). Another important issue is how long to treat patients safely with 
cyclosporine A. We did not document nephrotoxicity even in long term treated patients, 
perhaps because we used lower doses of the drug (<2- 3mg/kg/day) than usually reported. 
However, the optimal duration of the treatment is unknown. 
In our series cyclosporine A associated with intravenous immunoglobulin was successfully 
used both to control the disease activity and to keep the doses of glucocorticoids to a 
minimum. With this combined treatment we documented the best and statistically 
significant results as compared to steroid-cyclosporine A based treatment. This treatment 
was beneficial even in subjects with refractory disease and major organ involvement. We 
did not find any increase in the number or type of side effects. Further randomized trials 
may confirm the true benefits of various treatments in different subset of polymyositis and 
dermatomyositis. 
4. Mycophenolate mofetil and intravenous immunoglobulin in inflammatory 
myopathies  
4.1 Introduction 
Mycophenolate mofetil is an immunosuppressive drug mainly used in the prevention of 
allograft rejection in renal, cardiac or liver transplantation and in immune-mediated 
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diseases, such as systemic lupus erythematosus, with or without renal involvement 
(Bomback & Appel, 2010; Mok, 2007), systemic vasculitis (Hoffman, 2010), autoimmune 
rheumatic diseases (Iaccarino et al., 2007) and myasthenia gravis (Hehir et al., 2010). 
Mycophenolate mofetil is a prodrug of mycophenolic acid that was developed to enhance its 
bioavailability. Following oral administration, mycophenolate mofetil is entirely 
metabolized to mycophenolic acid. With regards to its action, mycophenolate mofetil is a 
potent selective inhibitor of inosina-5’-monophosphate dehydrogenase. Mycophenolate 
mofetil blocks the de novo synthesis of guanosine nucleotides, a critical pathway for the 
DNA synthesis in lymphocytes, acting on T- and B- cell proliferation and interfering on 
expression of adhesion molecules and on antibody production (reviewed in Ritter & 
Pirofski, 2009). Thus, mycophenolate mofetil could influence the course of cell- and 
antibody-mediated diseases.  
Despite its use in myositis since 2000, literature supporting the efficacy of mycophenolate 
mofetil is scarce with only case reports and a few small series. The following describes our 
experience with patients with polymyositis and dermatomyositis and compares our results 
with those of previous reports. 
4.2 Our experience with mycophenolate mofetil and intravenous immunoglobulin in 
inflammatory myopathies 
In an open study we prospectively followed up nine patients with polymyositis and 
dermatomyositis, the baseline characteristics are shown in the following table. Our previous 
positive experiences with intravenous immunoglobulin prompted us to treat them with a 
combined therapy based on intravenous immunoglobulin serial infusions and oral daily 
mycophenolate mofetil administration. 
In this series, polymyositis and dermatomyositis were diagnosed according to the Bohan 
and Peter’s criteria and the diagnosis was further confirmed by a muscle biopsy in all 
patients, except one case who declined. Indications for treatment were refractoriness to 
steroid (three cases) or two immunosuppressants given for at least two months (four cases) 
and glucocorticoids dependency (two cases). Overall patients received a median of two 
immunosuppressants (range from one to five) including methotrexate, cyclosporine A, 
cyclophosphamide, azathioprine and rituximab. The disease had a particularly aggressive 
course with myogenic damage predominating in the axial muscles in one case (F/49 with 
dermatomyositis) and cardiopulmonary involvement with cardiac arrhythmias and 
progressive decrease of lung function in another patient (FM/35 with dermatomyositis). At 
study entry, all of the patients had active myositis (see Table 1 for definition) with severe 
muscle involvement with difficult walking and dysphagia and/or dyspnoea. In subjects 
with dermatomyositis, the skin involvement was characterised by diffuse erythematosus 
and heliotrope rash. Median serum creatine kinase levels were above the normal range 
(Median ±SD = 1909±714; normal values < 170 IU/l). The initial oral mycophenolate mofetil 
dose of 500 mg/day was gradually increased to the definite dosage of 30 mg/kg/day in all 
of the patients with a subsequent median treatment duration of three years. As previously 
reported, intravenous immunoglobulin was infused at 1 g/kg (5g/hour) on two consecutive 
days each month for six months, followed by three further cycles given every other month. 
Prednisone was used according to our standard regimen. Previous immunosuppressants 
were withdrawn at the start of the study. Within two months of the start of the treatment an 
improvement in muscle strength with attenuation of cutaneous findings was observed.  
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Abbreviations: AZA, azathioprine; CSA, Cyclosporine A; CYC, cyclophosphamide; DM, 
dermatomyositis; IVM, intravenous methyl-prednisolone; IVIg, intravenous immunoglobulin; MMF, 
mycophenolate mofetil; MTX, methotrexate; PDN, prednisone; PM, polymyositis. 
Table 4. Baseline characteristics of nine patients with polymyositis or dermatomyositis 
treated with intravenous immunoglobulin associated with mycophenolate mofetil.  
During the subsequent follow-up period, the treatment with intravenous immunoglobulin 
and  mycophenolate mofetil enabled a significant improvement in the clinical (cutaneous 
and muscle strength) parameters, with a concomitant reduction of serum muscle enzymes 
and a progressive decrease and then disappearance of spontaneous pathological activity in 
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the sampled muscles at electromyographic studies performed at month 8 from the start of 
the treatment. In addition, we documented a significant improvement of Medical Research 
Council scale and modified Rankin score, the two main parameters employed to evaluate 
the muscle strength and the degree of disability, respectively. Another important result of 
this combined treatment was the statistically significant reduction of the daily prednisone 
dose. At the end of the follow-up period of nearly four years (49 ± 16 months), three of the 
patients (Table 4) showed a partial response, six were in complete remission. These 
successful results allowed us to withdraw mycophenolate mofetil in four patients who are 
now in remission with a low-dose prednisone. 
The treatment was well tolerated in all of the patients. The most prevalent complaint was 
represented by abdominal discomfort at the beginning of the mycophenolate mofetil 
treatment with a spontaneous resolution over time. In another patient, the administration of 
intravenous immunoglobulin was associated with mild headache which was subsequently 
resolved by reducing the infusion rate. Considering our complete series of patients with 
inflammatory myopathies treated with intravenous immunoglobulin, we detected a relative 
low prevalence of side effects (Table 5). 
 
Meningism  Withdrawn 1/36 (2%) 
Nausea e/o vomiting 




Resolution after paracetamol 
administration and/or infusion 
speed slowing down 
3/36 (8%) 
Table 5. Adverse events observed in our complete series of patients with polymyositis and 
dermatomyositis treated with intravenous immunoglobulin. Ten patients have been treated 
only with intravenous immunoglobulin, the other 26 with intravenous immunoglobulin 
associated with cyclosporine A (17) or mycophenolate mofetil (9). 
4.3 Literature review on the use of mycophenolate mofetil in inflammatory myopathies 
With regards to the literature on/relating to mycophenolate mofetil in inflammatory 
myopathies, the experience is still limited, since only case reports or predominantly 
retrospective small case series have been published. We performed a Medline search of 
English language from 2000 to 2011 related to the use of mycophenolate mofetil in 
dermatomyositis and polymyositis in adult patients. We analysed in particular the role of 
mycophenolate mofetil on muscle involvement. The literature search revealed that 62 
subjects (23 polymyositis and 39 dermatomyositis), including ours, have been reported to 
date. Indications for treatment were mainly refractoriness to glucocorticoids or to 
immunosuppressants  and prior intolerance to previous drugs employed to control the 
myositis (Danieli et al., 2009a). In two series (Chaudhry et al., 2001; Majithia & 
Harisdangkul, 2005) mycophenolate mofetil was used as initial immunosuppressive agent. 
The administration of mycophenolate mofetil, orally at 2 g daily, is linked to clinical 
improvement and decrease in serum creatine kinase levels in 73% of the subjects with 
polymyositis and in 77% of those with dermatomyositis. Mycophenolate mofetil is active 
even in cutaneous manifestations, initially documented by Gelber et al. (2000) in four 
patients with dermatomyositis refractory to glucocorticoids, hydroxychloroquine and 
methotrexate. Analysis of these reports appears to confirm our data that the association of 
intravenous immunoglobulin to mycophenolate mofetil may improve the proportion of 
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patients in remission and reduce the rate of side effects. Indeed, in approximately 30% of the 
responding patients (6/17 for polymyositis and 7/30 for dermatomyositis) remission was 
reached by a treatment based on intravenous immunoglobulin and mycophenolate mofetil 
even in refractory or particularly severe cases. The synergism in the action of intravenous 
immunoglobulin associated with mycophenolate mofetil is probably linked to the 
suppression of early stages of the activation and proliferation of lymphocytes. This 
synergism could even explain the relatively fast response (within one month in our 
experience) of the disease to the treatment, as it has been known that the onset of action of 
mycophenolate mofetil is usually delayed. In the literature, serum levels of mycophenolic 
acid, the active metabolite of mycophenolate mofetil, were not reported, probably as they 
are not usually performed in clinical practice. However, a recent paper on mycophenolate 
mofetil in kidney transplantation documented that patients exhibiting a lower rejection rate 
were those in whom the mycophenolate mofetil dose was not fixed but in accordance to 
serum mycophenolic acid levels (Le Meur et al., 2007). We cannot exclude that patients who 
did not respond to mycophenolate mofetil received a lower dose than necessary. 
Among the advantages linked to this combined therapy, there is the issue of drug-associated 
side effects. With regards to glucocorticoids, the majority of patients is able to taper or 
discontinue the dose of prednisone, thus significantly reducing the rate of side effects linked 
to its use.  
Concerning infective complications, the reported papers show a higher frequency and a 
greater severity of major side effects in dermatomyositis when compared to polymyositis. In 
their series of ten patients with dermatomyositis, Rowin et al. (2006) reported an 
exceedingly high rate of opportunistic infections (30%) that were, however, associated with 
contributing factors such as interstitial lung disease in two patients and previous treatment 
with cyclophosphamide in one patient. The same subject received a high mycophenolate 
mofetil dose (3 g daily). The third patient with opportunistic infection had open skin lesions 
predisposing her to Mycobacterium xenopi abscess of the left thigh. In those patients 
described in the literature in which mycophenolate mofetil was associated to intravenous 
immunoglobulin, no infectious complications were documented. It is conceivable that 
intravenous immunoglobulin enables a reduction in the infective risk in subjects treated 
with an immunosuppressant. This point is of particular interest since immunodeficiency 
states are increasingly recognised in patients with immune-mediated diseases and they are 
due to intrinsic defects linked to the disease itself and/or to the immunosuppressive drugs 
employed throughout the disease management. Diagnostic strategies have been recently 
addressed for rheumatic diseases (Samson et al., 2010). 
4.4 Other indications for mycophenolate mofetil  
A paper of Morath et al. (2006) suggests a cardioprotective role in vivo for mycophenolate 
mofetil due to its inhibitory effect on the proliferation of fibroblasts and vascular smooth 
muscle cells. This effect, if documented in larger series of patients, is of great importance, 
given the high rate of cardiovascular disease associated with inflammatory myopathies. In 
systemic lupus erythematosus, the data indicating a cardioprotective role of mycophenolate 
mofetil are, unfortunately, uncertain (Davies et al., 2009).  In cardiology, anti-inflammatory 
effects of intravenous immunoglobulin has been studied in some patients with heart failure, 
dilated cardiomyopathy, myocarditis, pericardial diseases, neonatal lupus (Nussinovitch & 
Shoenfeld, 2008).  
The choice of the immunosuppressant should be adjusted to the patient’s characteristics. For 
example, mycophenolate mofetil has no, theoretically, mutagenic potential but is teratogenic 
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in rats, rabbits and, probably, in humans. Atypical malformations (microtia or anotia in 
twelve newborns, external auditory canal atresia in nine and cardiovascular malformations 
in other six) in fourteen offspring of women exposed to mycophenolate mofetil in early 
pregnancy have been recently reported (Anderka et al., 2009). The underlying maternal 
conditions were different, ranging from kidney, liver or heart transplantation (nine 
patients), lupus nephritis (four cases), and recurrent erythema multiforme (one patient). No 
correlation between dose of mycophenolate mofetil and severity was noted. Hence when 
long-term immunosuppression is planned in a woman in child-bearing age, it is important 
to choose the immunosuppressant accordingly. Azathioprine and cyclosporine A can be 
safely used during pregnancy whereas mycophenolate mofetil and methotrexate are 
absolutely contraindicated.  
Another relevant issue, especially during economically restrained times, is that of cost. With 
regards to intravenous immunoglobulin, this point will be addressed in Paragraph 6. As for 
mycophenolate mofetil, the cost is generally ten times higher than that of other, older, 
immunosuppressants, such as azathioprine and cyclosporine A. However cost should be 
balanced against the effectiveness of the drug and its relative safety. 
5. Subcutaneous immunoglobulin 
5.1 Introduction 
The subcutaneous administration of immunoglobulin could be considered as an alternative 
to the more common intravenous route. Subcutaneous immunoglobulin is a blood product 
containing immunoglobulin G from normal subjects, initially used in primary 
immunodeficiency diseases and, more recently, in immune-mediated diseases or 
neurological conditions. In primary immunodeficiency, subcutaneous immunoglobulin 
used at replacement dosage, has been demonstrated to be linked to a lower incidence of 
adverse reactions, with reliable efficacy and improvement of the quality of life of treated 
subjects. Subcutaneous immunoglobulin has become increasingly popular in recent years, 
and now, the attention focuses on their possible use as a treatment of immune-mediated 
disease: we have been the first to publish on a series of seven patients with inflammatory 
myopathies successfully treated with subcutaneous immunoglobulin (Danieli et al., 2011).  
5.2 Proposed mechanism of subcutaneous immunoglobulin in inflammatory 
myopathies 
Like intravenous immunoglobulin, subcutaneous immunoglobulin could have multiple 
mechanisms, relevant to the pathogenesis of polymyositis and dermatomyositis (Vani et al., 
2008; Seite et al., 2008). Subcutaneous immunoglobulin treatment leads to more stable 
immunoglobulin levels, without peaks which are frequently responsible for side effects. 
However, since their kinetics is different from that of intravenous immunoglobulin, it is 
possible that subcutaneous immunoglobulin could act at different levels. Recent studies 
brought attention to the role of T-regulatory cells in autoimmune diseases, due to their role 
in suppressing the activation, the proliferation and the cytokine production of self-reactive T 
cells, thus contributing to the prevention of autoimmune phenomena and to the regulation 
of the immune homeostasis. Kessell et al. (2007), from the group of Professor Shoenfeld, 
were the first to demonstrate the direct influence of intravenous immunoglobulin on 
peripheral CD4+ CD25+ T-regulatory cells by increasing their suppressive function. 
Moreover, in the mouse model of experimental autoimmune myositis, which resembles 
www.intechopen.com
 
Immunoglobulin Treatment in Polymyositis and Dermatomyositis 
 
181 
human polymyositis in several aspects, the depletion of T-regulatory cells aggravated the 
disease, whereas the injection of polyclonal T-regulatory cells reduced both the incidence 
and the severity of the disease (Allenbach et al., 2009). Intravenous immunoglobulin 
treatment has also been shown to be effective in a mouse model for experimental allergic 
encephalomyelitis (Ephrem et al., 2008) increasing numbers and function of peripheral 
CD4+ CD25+ T-regulatory cells. Recent studies have demonstrated that intravenous 
immunoglobulin induces the expansion of T-regulatory cells and enhances their suppressive 
functions (Maddur et al., 2010). Even though no data is available on the action of 
subcutaneous immunoglobulin on T-regulatory cells, it can be hypothesised that in chronic 
autoimmune disease, such as inflammatory myopathies, the effects on T-regulatory cells 
exerted by subcutaneous immunoglobulin (von Gunten et al., 2008) could be more relevant 
due to the accelerated catabolism of pathogenic IgG, than intravenous immunoglobulin 
(Vani et al., 2008; Seite et al., 2008). 
5.3 Our experience with in subcutaneous immunoglobulin inflammatory myopathies 
Since 2009, January, we offered the option of subcutaneous immunoglobulin to our patients 
with idiopathic inflammatory myopathies (polymyositis or dermatomyositis) diagnosed 
according to the Bohan and Peter’s criteria. The disease was considered refractory, resistant 
or recurrent as shown in Table 1. Patients unable to follow instructions, with known allergic 
reaction to intravenous immunoglobulin, cancer-associated disease, inclusion body myositis 
or juvenile myositis, were excluded.  
At the start of our study, eight subjects agreed to perform the treatment with subcutaneous 
immunoglobulin: all the patients were Caucasian females; in all of them, the diagnosis was 
confirmed by a muscle biopsy, and the histological samples collected were examined by 
means of light and electron microscopy. Major findings were the changes in fibre size and 
the myofibers degeneration and regeneration with diffuse or focal inflammatory infiltrates, 
sometimes confined to the peri- and endomysium but usually interspersed between the 
individual muscle fibres as well. Perifascicular and perivascular inflammatory infiltrates 
were the typical findings in dermatomyositis. In all of the patients we performed nerve 
conduction and concentric needle electromyographic studies according to standard 
techniques that were repeated when clinically indicated. Fibrillation potentials and 
recruitment abnormalities were rated using commonly described methods (Wilbourn, 1993) 
and motor unit potentials were evaluated on the basis of their duration, configuration and 
amplitude by means of a trigger and delay line using a Nicolet Viking IV. At the start of 
subcutaneous immunoglobulin treatment, all the patients had active disease, confirmed by 
increased serum creatine kinase levels and the electromyographic findings. Clinically, they 
presented diffuse and persistent weakness due to severe muscle involvement with 
dysphagia in two cases and diffuse skin rash in four further cases. 
5.3.1 Treatment regimen 
At the beginning of treatment all the patients were taking oral prednisone at the previously 
assumed dose, maintained for at least one month. After this first period, prednisone was 
slowly tapered to an average of 0.25 mg/kg every other day. Two patients were treated only 
with prednisone, whereas the remaining patients were using it in addition to several other 
immunosuppressants. In particular, one patient was treated with oral cyclosporine A (3 
mg/kg/day in two refracted doses), two patients with oral mycophenolate mofetil (at 30 
mg/kg/day) and the last three patients with methotrexate (15 mg/week i.m.). During the 
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first three months of treatment with subcutaneous immunoglobulin, previous 
immunosuppressants were continued at the initial dose, and then, according to the patient’s 
clinical condition, these were slowly tapered.  
Prior to starting treatment with subcutaneous immunoglobulin all patients, apart from one 
case, were given immunoglobulin by the intravenous route at the dose of 2 g/kg, generally 
infused at 1 g/kg (5g/hour) on two consecutive days each month for at least six months. 
Four of them were successfully treated with intravenous immunoglobulin several years 
earlier. The three cases already in intravenous immunoglobulin treatment switched to the 
subcutaneous treatment one week after the last intravenous infusion, whereas the other 
patient directly began subcutaneous weekly infusion.  
5.3.2 Treatment with subcutaneous immunoglobulin 
At the beginning of the study, when we decided to treat our patients with inflammatory 
myopathies with subcutaneous immunoglobulin, one problem we encountered was dosage. 
We consequently decided to give patients the usual intravenous bimonthly dose (2g/kg) 
fractioned into equal doses given subcutaneously at weekly intervals: so, subcutaneous 
immunoglobulin (Vivaglobin ® CSL Behring) was infused weekly at the dose of 0.2 
g/kg/week, nearly double the dose infused in subjects with primary immunodeficiency 
diseases (Berger, 2008).  
Subcutaneous immunoglobulin administration needs a programmable pump (CRONO 
super PID), with a syringe capacity of 10, 20, 30 or 50 ml, depending on the producer. The 
site of administration must change for every infusion, choosing among arms, abdomen or 
thigh, allowing the administration of no more than 15 ml of the product (2.4 g of 
subcutaneous immunoglobulin) in the same subcutaneous area, at the infusion rate of 10 
ml/h into each site and, accordingly to the patient’s tolerance, it could be progressively 
increased up to 20-22 ml/h, according to the literature (Berger, 2008) and to what is 
currently advised in Italy. No premedication is required. 
5.3.3 Training of the patients 
A very important step for enhancing adherence to this kind of home regimen is training 
which can improve patient’s home-infusion experience and increase their acceptance of 
subcutaneous immunoglobulin. Therefore, all patients received an explicative brochure and 
were trained to perform home self-administration. Patients were even alerted about the 
potential problems linked to infusion and consequent management. In particular it is 
important to explain to them what might occur during infusion and how to minimise their 
own discomfort. It is essential to provide telephone support, so, a telephone emergency 
number was supplied to all patients. Best practice is reached by obtaining feedback on the 
process and its relative possible problems: a telephone follow-up should be conduced to 
evaluate the infusion experience and verify proper infusion techniques. The first two initial 
infusions were usually given in Day Hospital regimen with the aid of a physician and a 
nurse who instructed patients about performing subcutaneous infusion and explained the 
procedure to them: only when patients and a relative feel confident with the treatment, can 
further self-infusions be carried out at home.  
5.3.4 Results 
At 3-month evaluation, almost all patients showed a good response to the treatment, 
documented by creatine kinase serum levels normalisation, improvement in the Medical 
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research Council scale (a mean of 8 point) and in Rankin modified scores. Only two patients 
showed a partial response to the subcutaneous immunoglobulin treatment.  
Table 6 shows long-term follow-up analyses (a mean of 16.8 months). A marked beneficial 
clinical and laboratory response was documented in six patients in this series; they were all 
able to reduce the glucocorticoid dose and three of them were able to suspend the 
immunosuppressive agent. Even patients with relapsed disease showed a good response to 
subcutaneous immunoglobulin. Among these patients, the following briefly reports the 
history of a 69-year-old woman with a 2-year history of polymyositis, previously treated 
only with prednisone and methotrexate. She had never previously been treated with 
intravenous immunoglobulin. In her case, indication for the treatment with subcutaneous 
immunoglobulin was the appearance, after six months of treatment with methotrexate, of an 
elevated lymphocyte count (lymphocytes=4130 /mmc) with a  small clonal NK/T CD3+ 
CD4+ CD8+ CD56+ cell population (10% of the total circulating lymphocytes) bearing 
monoclonally the V/17 chain of TCR (90% of these CD4+ CD8+ cells). Due to the risk of 
progression to lymphoma linked to the use of methotrexate, we decided to discontinue this 
drug and to start the subcutaneous immunoglobulin treatment. After six months, with the 
patient’s muscle disease in remission, we documented the lymphocyte count normalisation 
and the clonal population reduction (70% of the CD4+ CD8+ cells).  
Among the partially responding patients is the case of a 39-year-old woman, presenting 
with long-term dermatomyositis (more than 20 years). From the onset, she showed a very 
aggressive form of the disease, with diffuse erythematosus and heliotrope rash, severe 
muscle involvement, characterised by weakness of the proximal and paraspinal muscles 
with a hanging head and an inability to execute any upward movement, rendering her 
dependent in performing daily activities. Over the years, she tried different types of 
therapeutic approaches; including methotrexate, cyclosporine A, high-dose glucocorticoids. 
The disease was eventually controlled only with serial infusion of intravenous 
immunoglobulin, which was maintained with increasing intervals for some years. In 
January 2009, she returned to our attention with a new relapse of the disease. She was 
immediately treated with high-dose prednisone, subsequently tapered, and intravenous 
immunoglobulin (2 g/kg) in monthly infusion for six months and then switched onto 
subcutaneous administration. After an initial positive response, at month 6, she had a flare-
up with persistent weakness and elevated serum creatine kinase levels requiring an 
intravenous immunoglobulin infusion (at the dose of 2 g/kg in two consecutive days) that 
brought the disease’s activity under control. The intravenous immunoglobulin was repeated 
three months later. In the subsequent follow-up period, while continuing the subcutaneous 
immunoglobulin, she was able to reduce the prednisone dose and despite this recurrence of 
disease, she showed a high level of satisfaction with treatment.  
One patient, a 74-year-old woman with polymyositis diagnosed on July 2006, had no 
response to subcutaneous treatment. She was initially treated with methyl-prednisolone (1 g 
per day for 3 days) followed by a decreasing dose of oral prednisone associated with 
methotrexate (10 mg/weekly i.m.) with a poor response. In 2008, she presented a recurrence 
of the disease with reduction in muscle strength and a marked increase in serum creatine 
kinase levels; we thus decided to start intravenous immunoglobulin at monthly cycles (2 
g/kg for each month), obtaining a good response. She subsequently switched to 
subcutaneous self-administration with clinical stabilisation, but without any laboratory 
improvement. At the first follow up visit, after one month, we noticed a slight increase of 
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Initial remission, but 
new flare-up after six 
months controlled by 
IVIg 
F/47 PM 151 
PDN, 
CYC, IVIg 





of PDN and MMF 
dosage 











F/43 DM 10 
PDN, 
MTX, IVIg 





reduction of PDN 
dosage 









F/74 PM 43 
PDN, 
MTX, IVIg 
Recurrence of a 
previously quiescent 
disease 
Poor response with 
slight improvement 
in muscular power 
and persistant 
elevation of CPK 
levels 








Withdrawn CSA and 
significant reduction 
of PDN dosage 
Abbreviations: anti-TNF, etanercept; CSA, Cyclosporine A; CYC, cyclophosphamide; IVIg, 
intravenous immunoglobulin; MMF, mycophenolate mofetil; MTX, methotrexate; OM, ocular myositis; 
PDN, prednisone; PP, plasmapheresis. 
Table 6. Baseline characteristics and treatment response in 8 patients treated with 
glucocorticoids and subcutaneous immunoglobulin. 
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Research Council scale. Moreover, laboratory tests showed an elevation on liver enzymes 
that induced a discontinuation of methotrexate and to introduce mycophenolate mofetil, by 
continuing the subcutaneous immunoglobulin infusion.  
In this series, we encountered the case of a 22-year-old-boy affected from infancy by an 
ocular form of myositis, previously refractory to different immunosuppressive therapies 
(cyclosporine A and methotrexate) and steroid-dependent. After starting the treatment with 
subcutaneous immunoglobulin, he was able to discontinue the immunosuppressants and to 
gradually reduce the prednisone (used for 15 years of his life).  
In all of the responding patients, the subcutaneous administration of immunoglobulin was 
continued one year after remission, associated in most cases with a low-dose prednisone. 
5.3.5 Patient satisfaction with subcutaneous immunoglobulin 
Satisfaction with the subcutaneous immunoglobulin treatment was high in all patients. At 
the end of the follow-up period we documented an improvement in our patient’s quality of 
life, the highest scores being for global mental health, measured using the validated Italian 
version of the Medical Outcome Study Short Form 36 (SF-36) questionnaire, which has two 
major domains – physical health and mental health indexes – and measures physical activity 
and restrictions, physical pain, global health status, vitality, social and occupational 
activities, restrictions and mental health (Apolone & Mosconi, 1998). We investigated patient 
interest in and satisfaction with the treatment, and the quality of communication provided 
by the staff, testing the level of agreement with a statement. The most significant items 
suggested by the patients were the reduction in problems while receiving treatment and the 
increased freedom in organizing daily activities. Considerable satisfaction was felt with the 
quality of disease-related information, its usefulness in treatment management and the high 
level of communication with health professionals. 
5.3.6 Side effects with subcutaneous immunoglobulin 
In our series, no major side effects were documented. In literature, systemic adverse effects 
have been reported in less than 1% of subcutaneous infusions, as opposed to 5% of 
intravenous infusion (Berger, 2008). These only include mild local reactions, including 
swelling, redness and “burning” sensation in the infusion site that usually resolve 
spontaneously within 24-48 hours, as reported in literature (Wasserman, 2008). These effects 
were transient and declined over time, specifically after 8 to 10 weeks. The recording of side 
effects is subjective and it is possible that very weak reactions were not mentioned by the 
patients, due to their acceptance of the treatment and to their gradual adaptation to the local 
phenomena.  
The different pharmacokinetic properties between intravenous and subcutaneous 
immunoglobulin regimens reflect the differences in their adverse effects. Despite not 
checking the serum IgG levels in our patients, it is conceivable that fractioning the usual 
monthly intravenous dose into subcutaneous weekly doses facilitated near stable IgG levels. 
It is likely that the metabolised IgG are constantly being replaced by IgG freshly absorbed 
from the subcutaneous injection site. Taking this into account, the subcutaneous route 
administration and the reduced dose given in weekly subcutaneous infusion could lead to a 
reduction in the risk of systemic reactions and of thromboembolic events. It is noteworthy 
that various reports described the safe use of subcutaneous immunoglobulin in patients 
with previous serious systemic adverse reactions to intravenous immunoglobulin (Quinti et 
al., 2008).  
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Finally, the global costs of subcutaneous immunoglobulin treatment, are usually 15-25% less 
than those of intravenous immunoglobulin treatment as later reported (Paragraph 6). 
Furthermore, the ability to use subcutaneous immunoglobulin in patients with difficult 
venous access or in those with associated selective IgA deficiency, of course after a 
tolerability check given the variable individual response of the IgA deficient patients, will in 
future make subcutaneous immunoglobulin as the first choice. 
5.4 Subcutaneous immunoglobulin in other immune-mediated diseases 
Although subcutaneous self-infusion of immunoglobulin is currently labelled and 
increasingly used for replacement therapy in primary immune deficiencies, with 
documented effectiveness and safety, only a few cases report the use of subcutaneous 
immunoglobulin for its immunomodulatory and anti-inflammatory properties in chronic 
inflammatory disease.  
In a case report, subcutaneous immunoglobulin was successfully used as an adjuvant 
treatment in a subject with dermatomyositis (Schleinitz et al., 2008) after 1-year follow-up.  
Other experiences with subcutaneous immunoglobulin as a treatment of chronic 
inflammatory disease were carried out in particular for immune-mediated neurological 
disorder, as multifocal motor neuropathy or chronic inflammatory demyelinating 
polyneuropathy.  
A preliminary experience was reported by Koller at al. (2006) in three subjects with chronic 
inflammatory demyelinating polyradiculoneuropathy with relapses, in which the use of 
subcutaneous immunoglobulin (at the dose of 0.1 g/kg of body weight given once weekly 
for 6 months), in concomitance with mycophenolate mofetil, lead to a stable disease during 
the 6-month follow-up period. Subsequently, Harbo et al. (2009) performed a randomized 
single-blind cross-over study on nine intravenous immunoglobulin responsive patients 
suffering from multifocal motor neuropathy, directly comparing the subcutaneous and the 
intravenous route, given in sequence, showing that using equivalent doses, the effectiveness 
of two treatments is similar in  regard to muscular strength. No significant differences 
between treatments on health-related quality of life occurred, but as suggested by the 
authors and by Dimberg (2009), who discussed this data the relatively short treatment 
period may have played down subcutaneous immunoglobulin. In this regard, he performed 
another study, showing that long-term subcutaneous immunoglobulin therapy is an 
alternative approach to intravenous immunoglobulin that is desirable for some patients 
(Dimberg, 2009) in a small case series of six intravenous immunoglobulin responsive 
patients with multifocal motor neuropathy on long-term subcutaneous immunoglobulin 
maintenance therapy with dose equivalent to their previous intravenous regimen, followed 
for two years. Five of them preferred to continue the subcutaneous administration after the 
trial and another patient chose to apply for this kind of treatment. A case report on a patient 
with multifocal motor neuropathy positively treated for six months and in maintenance 
therapy with subcutaneous immunoglobulin was described by an Italian group (Dacci et al., 
2010). Similar results were reported by Eftimov et al. (2009); in his single-centre open-label 
pilot intervention study, ten patients affected by multifocal motor neuropathy treated with 
intravenous immunoglobulin were included and then they were switched to weekly 
subcutaneous immunoglobulin. The first group (five patients) started with a subcutaneous 
dose equivalent to 50% of the intravenous dose, and then, in case of deterioration they 
received a loading dose of intravenous immunoglobulin and doubling of subcutaneous 
dose. The second group (five patients) started with a dose equivalent to the intravenous 
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maintenance dose. They demonstrated that in four patients, the subcutaneous 
immunoglobulin therapy was feasible and safe and maintained strength as well as the 
intravenous route, while in the latter case a higher dose was needed; he brought attention to 
the subcutaneous dose as a maintenance treatment, monitoring serum immunoglobulin 
concentrations. Whereas patients in intravenous treatment show a swinging trend of 
immunoglobulin levels, with spikes corresponding to the therapy and deep valleys in the 
interim periods, during subcutaneous immunoglobulin treatment, immunoglobulin levels 
appeared stable and slightly higher than normal, preventing end- of-dose weaving observed 
in intravenous treatment. In previous experiences in primary immunodeficiency patients 
treated with subcutaneous immunoglobulin, it was documented that the mean serum IgG 
levels are usually higher than those obtained by the intravenous route when using the same 
total monthly dose (Berger, 2008). 
6. Cost of the immunoglobulin treatment 
The use of intravenous immunoglobulin is linked to the well known problems of supply 
and costs. First of all, the decision to use intravenous immunoglobulin for the treatment of 
myositis should be made in consultation with an expert in neuromuscular disease. Before 
treatment, it is essential to have a pathologic confirmation by means of a skeletal muscle 
biopsy for the diagnosis of polymyositis or dermatomyositis. As recommended by Feasby et 
al. (2007), the muscle specimen must be procured, processed, and interpreted in a 
specialised laboratory and the final diagnosis must be made by an expert in neuromuscular 
pathology. Once a diagnosis is obtained, immunoglobulin should be used in accordance 
with the main international guidelines (Feasby et al., 2007; Elovaara et al., 2008) and local 
directives. 
The preparation of immunoglobulin is a multi-step process that leads to different products 
as supplied by manufacturers (Gurcan, 2010). In order to discover the real benefits of 
(intravenous or subcutaneous) immunoglobulin therapy in health-economical terms, 
analyses must be performed in each country, since economic systems for the provision of 
healthcare, including pharmacy handling, vary substantially (Gardulf, 2007). Most of these 
data, unfortunately, are inadequate and the majority of the reports published in the 
literature are related to the pharmacoeconomic evaluation on the use of intravenous or 
subcutaneous immunoglobulin in patients with antibody deficiency. 
The first ever health-economic evaluation of immunoglobulin therapy has been performed 
in Sweden (Gardulf, 1995). It showed that the change from in-hospital intravenous 
immunoglobulin therapy to home-based subcutaneous immunoglobulin treatment saved 
$US10.100 per patient per year (1993 annual costs). All factors being equal, the use of 
subcutaneous immunoglobulin self-infusions at home for 80% of the 1300 Swedish patients 
known to be using immunoglobulin replacement therapy today would lead to a cost 
reduction of $US 10.504.000 per year for Swedish society. A recent cost analysis in Germany 
showed that a switch of 60% of the patients on intravenous to subcutaneous 
immunoglobulin therapy would lead to the German health insurance system saving 
between €17 million and €77 million each year (Hogy et al., 2005).  
In the US, it has also been calculated that the cost of subcutaneous immunoglobulin self-
infusions at home is $US 48, compared with $US 164–314 for using intravenous 
immunoglobulin at home administered by nurses (Radinsky & Bonagura,  2003) and that “it 
may be expected that cost savings of $US2000–5000 per patient per year” will be the result of 
home instead of hospital therapy (Berger, 2003).  
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In Italy the only cost-minimisation analysis has been performed by Matucci et al. (2008) 
using data from the Tuscany Health Service. It compares the annual direct medical costs 
(immunoglobulin, premedication, infusion pump, infusion materials, medical staff, 
ambulatory) of subcutaneous and intravenous immunoglobulin in patients with antibody 
deficiency observing a difference of € 2,212.98  in favour of subcutaneous immunoglobulin 
due to lower costs for both medical staff and ambulatory. The Italian experience, in 
accordance with the literature, substantiates the cost-sparing effect of subcutaneous 
immunoglobulin home treatment from both patient and medical point of view. It is 
important to note that the production of intravenous immunoglobulin is more complex than 
that of subcutaneous immunoglobulin, thus largely rendering the latter a more viable option 
in regards to overall yield. Moreover, home management lead to a reduction in the costs 
linked to hospitalisation, substantially reducing the time and the workload necessary for the 
department to handle the intravenous therapy of patients. Indirect costs that favour the use 
of subcutaneous immunoglobulin are transportation to hospital and time lost from work 
(Gaspar et al., 1998).  
Another concern regarding the costs of intravenous immunoglobulin therapy is the frequent 
need of their use as maintenance therapy after the initial remission. Dalakas (2006) 
documented that the benefits appear lasting an average of six weeks and that for long-term 
benefits, continued infusions may be required. Genevay et al. documented that low-dose 
(0,8 g/kg/monthly) treatment with intravenous immunoglobulin can be helpful in 
maintaining clinical remission after high-dose initial infusions (2g/kg/monthly) in patients 
with refractory polymyositis (Genevay, 2001).  
However, the problem of cost should be balanced with proven effectiveness in otherwise 
life-threatening situations or as short-term treatment in patients with severe refractory 
disease. 
7. Conclusions 
In this chapter we examined the role of immunoglobulin therapy in polymyositis and 
dermatomyositis. The revision of the literature evidenced the lack of randomised controlled 
trial, basically due to the rarity of the diseases. Another major problem in evaluating the 
published reports in polymyositis and dermatomyositis is the lack of international 
consensus on diagnostic criteria and outcome measures. A consensus on this will 
significantly improve the analyses of published data. Despite these biases, most of the 
papers report the efficacy and the safety of intravenous immunoglobulin, when standard 
therapeutic regimens fail, even in refractory or relapsing cases. Indication for the use of 
intravenous immunoglobulin is in particular the oesophageal involvement. In other reports 
intravenous immunoglobulin is used in association with immunosuppressants. In relation to 
cyclosporine A and mycophenolate mofetil, the add-on of intravenous immunoglobulin 
enables an increase in the rate of responding patients, with a short- and long-term stable 
remission and a reduced rate of infective complications. Recently, subcutaneous 
immunoglobulin has been used in selected autoimmune diseases. We documented the 
feasibility and the high tolerability of subcutaneous immunoglobulin, with relevant 
improvement in the clinical and laboratory features. Moreover, subcutaneous 
immunoglobulin increases patient quality of life giving them the possibility to receive 
treatment at home. This “self-management” is generally appreciated by most patients, in 
particular as it renders them independent from healthcare providers and hospitalisation, 
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with a significant improvement in treatment satisfaction. This improvement is mostly 
associated with flexibility, reduced infusion-related issues and enhanced freedom in 
organising daily activities. The low rate of side effects which improves quality of life, the 
possibility to withdraw the immunosuppressants and the steroid sparing effect, make the 
subcutaneous immunoglobulin a viable option in selected patients with myositis when 
standard therapeutic regimens fail or when immunosuppressants are contra-indicated. 
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